Global Veterinary CRO and CDMO Market Overview Highlights Outsourcing Momentum in Animal Health
The Veterinary CRO and CDMO market was valued at USD 6.23 billion in 2023 and is projected to reach USD 13.3 billion by 2032, expanding at a CAGR of 8.84% during 2024–2032. This growth reflects a structural shift in the animal health ecosystem, where pharmaceutical and biotech companies increasingly rely on contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) to streamline veterinary drug development, clinical trials, and large-scale production.
The Veterinary CRO and CDMO market report evaluates regional disease prevalence, veterinary prescribing trends, and the penetration of pharmaceuticals, biologics, and feed additives. It also examines veterinary healthcare expenditure patterns across government funding, insurance, and out-of-pocket spending, highlighting how rising investments in animal health are translating into higher outsourcing demand.
Stay Ahead with Market Trends: Access Your Sample Report Now: https://www.snsinsider.com/sample-request/6019
Increasing Pet Population and Livestock Expansion Drive Market Growth
The primary growth engine of the Veterinary CRO and CDMO market is the rapid expansion of the global pet population alongside intensified livestock production. As of 2024, the global pet population exceeds 1 billion animals, with cats ranking as the most owned pets worldwide. Nearly 47% of pet owners are first-time owners, underscoring sustained long-term demand for veterinary medicines, vaccines, and diagnostics.
Parallel to this trend, livestock production is scaling up to meet global food security needs. India’s milk production reached 239.30 million tonnes in 2023–24, representing a 3.78% year-on-year increase and reinforcing its position as the world’s largest producer. Such growth places immense pressure on animal health systems, increasing reliance on Veterinary CRO and CDMO services to develop effective vaccines and treatments that ensure productivity and disease prevention.
Veterinary CROs and CDMOs play a pivotal role by offering species-specific research, regulatory expertise, and manufacturing scalability, enabling animal health companies to bring products to market faster while maintaining compliance.
High R&D Costs and Regulatory Complexity Limit Smaller Players
Despite strong growth prospects, the Veterinary CRO and CDMO market faces notable restraints. High research and development costs remain a major barrier, particularly for smaller and mid-sized companies. Advanced clinical trials, especially late-stage studies, can cost over USD 100 million per trial, discouraging innovation among resource-constrained developers.
Regulatory compliance further compounds these challenges. Agencies such as the European Medicines Agency enforce stringent frameworks like Regulation (EU) 2019/6, which governs veterinary medicinal products. Navigating diverse regulatory standards across regions increases approval timelines and operational costs.
Additionally, global concerns around antimicrobial resistance have resulted in tighter controls on antibiotic use in animals. Restrictions on prophylactic and non-therapeutic antibiotic applications have intensified regulatory scrutiny, requiring CROs and CDMOs to adopt more rigorous testing, monitoring, and reporting protocols.
Personalized Veterinary Medicine Emerges as a High-Value Opportunity
The rising adoption of personalized veterinary medicine presents a compelling opportunity for the Veterinary CRO and CDMO market. Tailoring treatments based on an animal’s genetics, breed, and health profile improves therapeutic outcomes while optimizing cost efficiency.
In the United States alone, pet-related spending reached USD 147 billion in 2023, with USD 38.3 billion allocated to veterinary care. This reflects a willingness among pet owners to invest in advanced and customized treatments. However, escalating service costs—up 6.2% between July 2023 and July 2024—have also led to financial stress, with 91% of pet owners reporting concerns over affordability.
By supporting personalized treatment development, Veterinary CROs and CDMOs can help pharmaceutical companies design targeted therapies that reduce long-term care costs while enhancing treatment efficacy.
Ethical Concerns Around Animal Testing Present Industry Challenges
Ethical scrutiny surrounding animal testing remains a significant challenge for the Veterinary CRO and CDMO market. Public sentiment increasingly favors alternative research methods, with 85% of Americans in 2024 supporting the replacement of animal experiments with modern techniques.
Globally, an estimated 200 million animals are used annually in medical research, and in the U.S., unmitigated pain or distress procedures rose by 9% in 2023, affecting over 62,000 animals. These statistics have intensified calls for stricter oversight, increased transparency, and the adoption of alternative testing models.
CROs and CDMOs must balance ethical responsibilities with scientific rigor by investing in refined protocols, in-vitro models, and data-driven simulation technologies to meet regulatory and societal expectations.
Livestock Segment Dominates Market by Animal Type
By animal type, the livestock segment accounted for 63% of total revenue in 2023, making it the largest contributor to the Veterinary CRO and CDMO market. Large-scale farming operations demand consistent access to vaccines, therapeutics, and preventive solutions to maintain herd health and productivity.
Government initiatives aimed at food safety and animal welfare further support this segment. In the European Union, livestock disease prevention strategies are integral to agricultural productivity goals, creating sustained demand for CRO and CDMO services focused on livestock health.
Development Services Lead by Service Type
The development segment held over 31% of market revenue in 2023, reflecting the growing complexity of veterinary therapeutics. Drug discovery, formulation, and regulatory development services are increasingly outsourced to specialized providers to meet stringent safety and efficacy requirements.
Government-backed research initiatives, including grants and academia–industry collaborations, further strengthen the development pipeline. Regulatory oversight from authorities such as the U.S. Food and Drug Administration reinforces the importance of structured development services in the Veterinary CRO and CDMO market.
High Demand for Market Insights: Discover Comprehensive Trends in Our Full Report: https://www.snsinsider.com/reports/veterinary-cro-and-cdmo-market-6019
Veterinary Medicines Dominate Application Landscape
By application, the medicine segment emerged as the largest contributor in 2023. Rising cases of zoonotic diseases, cancer, and chronic conditions in animals are driving demand for innovative veterinary pharmaceuticals.
Advancements in diagnostics and treatment technologies enable earlier detection and more precise interventions, further reinforcing the dominance of this segment. Government health agencies continue to emphasize the importance of effective animal disease management to protect public health, indirectly supporting pharmaceutical innovation.
North America Leads While Asia Pacific Shows Fastest Growth
North America held the largest market share in 2023 due to advanced animal health infrastructure and strong government support. Agencies such as the USDA’s Animal and Plant Health Inspection Service play a crucial role in maintaining regional leadership.
Europe follows closely, supported by robust animal welfare regulations and increasing pet ownership. Meanwhile, the Asia Pacific region is projected to be the fastest-growing market through 2032, driven by expanding veterinary infrastructure in China and India, along with cross-border collaborations that accelerate technology adoption.
Key Players
Charles River Laboratories, Vetio, LABIANA Group, TriRx Pharmaceutical Services, Aenova Group, Oncovet Clinical Research (OCR), Argenta Group (KLIFOVET GmbH), Clinvet, VETSPIN, Knoell, IDEXX Laboratories Inc., CZ Vaccines, Kela Health, Argenta Limited, AB7 Group, Labcorp Drug Development, Zoetis Inc., Inotiv Inc., Jubilant Biosys, Syneos Health Inc.
Future Outlook
The future of the Veterinary CRO and CDMO market is defined by increasing outsourcing, personalized medicine adoption, and regional expansion in emerging economies. Continued investment in ethical research practices, regulatory compliance, and advanced manufacturing technologies will be critical in sustaining long-term growth.
Conclusion
The Veterinary CRO and CDMO market is undergoing a transformative phase as animal health gains global prominence. Driven by rising pet ownership, livestock expansion, and innovation in veterinary medicine, CROs and CDMOs are becoming indispensable partners in the animal health value chain. While regulatory and ethical challenges persist, evolving technologies and personalized care models are expected to unlock new growth avenues through 2032.
Explore SNS Insider Related Ongoing Coverage on Healthcare Market Insights Domain:
Frequently Asked Questions
What was the valuation of the Veterinary CRO and CDMO market in 2023?
The market was valued at USD 6.23 billion in 2023.
What is the projected market size by 2032?
The Veterinary CRO and CDMO market is expected to reach USD 13.3 billion by 2032.
What is the expected CAGR during the forecast period?
The market is projected to grow at a CAGR of 8.84% from 2024 to 2032.
Which segment dominates the Veterinary CRO and CDMO market?
The livestock animal segment dominates, accounting for 63% of revenue in 2023.
Which region is expected to grow the fastest?
Asia Pacific is expected to witness the fastest growth during the forecast period due to expanding veterinary infrastructure and rising demand.
